Evommune says EVO756 phase 2b failed in atopic dermatitis
Evommune said EVO756 in moderate-to-severe atopic dermatitis did not meet primary or secondary endpoints and will be discontinued for AD.
Evommune announced EVO756 Phase 2b in moderate-to-severe atopic dermatitis did not meet primary or secondary endpoints and will be discontinued for AD.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain inaccuracies.
Conside…